A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.
Green AK, Zhou Q, Iasonos A, Zammarrelli WA, Weigelt B, Ellenson LH, Chhetri-Long R, Shah P, Loh J, Hom V, Selenica P, Erinjeri J, Petkovska I, Chandarlapaty S, Cohen S, Grisham R, Konner J, Rubinstein MM, Tew W, Troso-Sandoval T, Aghajanian C, Makker V.
Green AK, et al. Among authors: zhou q.
Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1999. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 39561275